References Annual review of factor replacement products. Oklahoma Health Care Authority Review Board. Updated April 2016. https://oklahoma.gov/ohca.html. Accessed April 1, 2022. Burke T, Asghar S,...

PTC Therapeutics is awaiting the FDA decision for ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The FDA granted ataluren Fast Track and Orphan Drug...

Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned ourselves to best prepare our clients to manage new drugs. Our clinical and trade...

publications What 2025 Revealed About the Future of Oncology Care January 14, 2026 Author: Simone Ndujiuba, PharmD, BCOP Over the past year, Oncology Insights highlighted the oncology topics...

With an established playbook for launching new union business, we ensure smooth transitions, clear communication and rapid implementation. Our Special Investigations Unit (SIU) uses advanced...

publications High Cost Therapy Profile: November 2024 Zenocutuzumab Intravenous (IV) Oncology Proposed indications Pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC)...

Merck submitted a combination product containing pembrolizumab and berahyaluronidase alfa as a subcutaneous (SC) version of pembrolizumab (Keytruda) for approval across all previously approved...

Plozasiran, by Arrowhead, is a first-in-class RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3), thereby reducing circulating triglycerides (TG). It...